Pablo Ayala-de Miguel

5PUBLICATIONS
14CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 16, 2026
Real-world experience of clinicopathological features and survival predictors in radioactive iodine-refractory differentiated thyroid cancer treated with multi-kinase inhibitors: a multicentre study from southeastern Spain.

|Jul 07, 2026
Real-world effectiveness of chemotherapy regimens after immunotherapy in patients with advanced melanoma in Spain: Results from the GEM1801 study.

|May 27, 2026
Impact of Immune-Related Adverse Event Frequency, Severity and Corticosteroid Use on Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer.

|Jul 27, 2025
Retreatment and rechallenge with BRAF/MEK inhibitors in patients with metastatic melanoma: results from the real-world Spanish Melanoma Registry (GEM-1801).

Pablo Ayala-de Miguel, Eva Muñoz-Couselo, Lourdes Gutiérrez-Sanz

|Jul 12, 2025
Real-World Data on Immune-Checkpoint Inhibitors in Elderly Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Study.

José Del Corral-Morales, Carlos Ayala-de Miguel, Laura Quintana-Cortés

Pageof 1

Frequent Collaborators

2 joint publications

Iván Márquez-Rodas

1 joint publications

Miguel-Ángel Berciano-Guerrero

1 joint publications

Elisabeth Pérez-Ruiz

1 joint publications

Eva Muñoz-Couselo